Companies › Portage Biotech
2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| TT-10 | – | Phase 1 | Renal Cell Cancer | Dec 2028 |
| TT-4 | – | Phase 1 | Renal Cell Cancer | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04969315 | TT-10 | Phase 1 | Renal Cell Cancer | Oncology | Dec 2028 |
| NCT04969315 | TT-4 | Phase 1 | Renal Cell Cancer | Oncology | Dec 2028 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.